What is the current stock price of Teva Pharmaceutical Industries Limited (TEVA)?

As of the latest market data, Teva Pharmaceutical Industries Limited (TEVA) is trading at $30.82. The stock has seen a loss of -0.45% today.

Does Teva Pharmaceutical Industries Limited (TEVA) pay a dividend?

Based on current data, Teva Pharmaceutical Industries Limited does not have a confirmed active dividend policy.

What is the market cap of Teva Pharmaceutical Industries Limited?

The current market capitalization of Teva Pharmaceutical Industries Limited (TEVA) is approximately unavailable.

TEVA

Teva Pharmaceutical Industries Limited·Healthcare

30.82

0.452%(−0.14)

Market Closed

31.30

1.557%(+0.48)

After Hours

Last Updated: — ET

52W L: $13.0452W H: $37.35

TEVA NEWS

zacks.com

Mar 31

TEVA's Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted

Teva wins FDA approval for Prolia biosimilar Ponlimsi and secures Xolair biosimilar filing review by the FDA and EMA, strengthening its biosimilars push.

globenewswire.com

Mar 30

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its biosimilar portfolio, demonstrating continued momentum in the advancement of its Pivot to Growth strategy. The United States (U.S.) Food and Drug Administration (FDA) has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia ® , and Teva's applications for a proposed biosimilar candidate to Xolair ® (omalizumab) have been accepted by both the U.S. FDA and the European Medicines Agency (EMA).

defenseworld.net

Mar 26

E. Ohman J or Asset Management AB Takes Position in Teva Pharmaceutical Industries Ltd. $TEVA

E. Ohman J or Asset Management AB purchased a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 19,680 shares of the company's stock, valued at approximately $614,000. A number of

defenseworld.net

Mar 22

Hudson Bay Capital Management LP Acquires 105,000 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Hudson Bay Capital Management LP grew its stake in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 87.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 225,000 shares of the company's stock after acquiring an additional 105,000 shares during the

globenewswire.com

Mar 19

Teva Releases Q1 2026 Aide Memoire

TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its website.

globenewswire.com

Mar 19

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

37,000

IPO Date

1982-02-16

Beta

0.76

Websitewww.tevapharm.com↗